[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.142.219. Please contact the publisher to request reinstatement.
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]
Citations 0
From the Centers for Disease Control and Prevention
January 17, 2001

Respiratory Syncytial Virus Activity—United States, 1999-2000 Season

JAMA. 2001;285(3):287-288. doi:10.1001/jama.285.3.287-JWR0117-3-1

MMWR. 2000;49:1091-1093

1 figure omitted

Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract illness (LRTI) among infants and children worldwide1 and is an important cause of LRTI among older children and adults.2 Despite the presence of maternal antibodies, most hospitalizations occur among infants aged <6 months, and nearly all children are infected by age 2 years.3 Although primary infection is usually most severe, reinfection throughout life is common.4 In temperate climates, RSV infections occur primarily during annual outbreaks, which peak during winter months.5 In the United States, RSV activity is monitored by the National Respiratory and Enteric Virus Surveillance System (NREVSS), a voluntary, laboratorybased system. This report summarizes trends in RSV activity reported to NREVSS from July 1999 through June 2000 and presents preliminary surveillance data from July 8 through November 21, 2000, which indicate that RSV community outbreaks are becoming widespread.

Clinical and public health laboratories report weekly to CDC the number of specimens tested for RSV by antigendetection or virusisolation methods and the number of positive results. RSV activity is considered widespread by NREVSS when (1) >50% of participating laboratories report one or more RSV detections for at least 2 consecutive weeks, and (2) >10% of all specimens tested for RSV during a surveillance week are positive. Of the laboratories reporting data for the week ending November 4, 2000, 32 (53%) detected >10% of specimens positive for RSV for at least 2 consecutive weeks, indicating the onset of widespread RSV activity for the 2000-01 season.

From July 1999 through June 2000, 72 laboratories in 45 states reported 123,769 tests for RSV; 18,981 (15%) were positive for RSV. In the United States, widespread RSV activity began during the week of October 30, 1999, and continued for 26 weeks, until the week of March 25, 2000. The timing of the onsets and conclusions of RSV regional outbreaks varied by state: range at onset was September 18 to January 29 and range at conclusions was January 29 to May 6. Regional RSV outbreaks occurred earliest in the South (23 sites; median weeks of onset and conclusion: October 16 and March 11, respectively), later in the Northeast (10 sites; November 27 and April 15), and latest in the Midwest (11 sites; December 28 and April (1) and West (12 sites; November 13 and April 8).*

Although 92% of positive tests were reported for the week ending October 30 through the week ending March 25, RSV was detected throughout the year. For example, during July-August 1999, sporadic RSV isolates were reported from laboratories in California, Colorado, Florida, Hawaii, Louisiana, Texas, Virginia, and Washington.

For the July 1999–June 2000 surveillance period, the number of specimens that tested positive for RSV, average months of peak activity, and regional trends were similar to trends observed during previous years. The duration of the 1999-2000 RSV season also was consistent with that of previous years, including the typical earlier onset of RSV outbreaks reported by southern laboratories.

Reported by:

National Respiratory and Enteric Virus Surveillance System collaborating laboratories. Respiratory and Enteric Viruses Br, Div of Viral and Rickettsial Diseases, National Center for Infectious Diseases, CDC.

CDC Editorial Note:

Severe manifestations of RSV infection (e.g., pneumonia and bronchiolitis) most commonly occur among infants aged 2-6 months, and hospitalization rates for these diagnoses have been used as an indicator for severe RSV disease among young children. In the United States, bronchiolitis hospitalization rates among children aged <1 year were 31.2 per 1000 in 19966 and were 61.8 per 1000 children aged <1 year among American Indian/Alaska Native children receiving care through the Indian Health Service.7

NREVSS consists of 84 widely distributed laboratories and permits characterization of geographic and temporal trends of RSV infections in the United States. NREVSS data can alert public health officials and physicians to the timing of seasonal RSV activity. Although no RSV vaccine is available, RSV immune globulin intravenous and a humanized murine antiRSV monoclonal antibody are recommended as prophylaxis for some high risk infants and young children (e.g., those born prematurely or with chronic lung disease) to prevent serious RSV disease.8 Nosocomial transmission of RSV can be controlled by using contact isolation procedures.

The findings in this report are subject to at least three limitations. First, laboratory data serve as an indicator of when RSV is circulating in a community; however, the correlation of these data to disease burden in the population is uncertain. Second, some regions are represented by few laboratories. Finally, the results may not be confirmed in some laboratories.

Symptomatic RSV disease can recur throughout life because of limited protective immunity induced by natural infection. As a result, healthcare providers should consider RSV as a cause of acute respiratory disease in children and adults during community outbreaks. Persons with underlying cardiac or pulmonary disease or compromised immune systems and the elderly are at increased risk for serious complications of RSV infection, such as pneumonia and death.9 RSV infection among recipients of bone marrow transplants has resulted in high mortality rates (83%).10 Additional information and updated data on RSV trends are available on the CDC WorldWide Web site at http://www.cdc.gov/ncidod/dvrd/nrevss.

Back to top
Article Information
*Northeast = Connecticut, Maine, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, and Vermont; Midwest = Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio, South Dakota, Wisconsin; South = Alabama, Arkansas, Delaware, District of Columbia, Florida, Georgia, Kentucky, Louisiana, Maryland, Mississippi, North Carolina, Oklahoma, South Carolina, Tennessee, Texas, Virginia, and West Virginia; West = Alaska, Arizona, California, Colorado, Hawaii, Idaho, Montana, Nevada, New Mexico, Oregon, Utah, Washington, and Wyoming.
References
1.
Institute of Medicine, Prospects for immunizing against respiratory syncytial virus. Institute of Medicine. New vaccine development: establishing priorities. Vol II. Disease importance in developing countries Washington, DC National Academy Press1986;299- 307
2.
Falsey  ARWalsh  EE Respiratory syncytial virus infection in adults. Clin Micro Reviews. 2000;13371- 84Article
3.
Glezen  WPTaber  LHFrank  ALKasel  JA Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child. 1986;140543- 6
4.
Henderson  FWCollier  AMClyde Jr  WADenny  FW Respiratory syncytial virus infections: reinfections and immunity. N Engl J Med. 1979;300530- 4Article
5.
Gilchrist  STorok  TJGary Jr  HEAlexander  JPAnderson  LJ National surveillance for respiratory syncytial virus, United States, 1985-1990. J Infect Dis. 1994;170986- 90Article
6.
Shay  DKHolman  RCNewman  RDLiu  LLStout  JWAnderson  LJ Bronchiolitis-associated hospitalizations among U.S. children, 1980-1996. JAMA. 1999;2821440- 6Article
7.
Lowther  SAShay  DKHolman  RCClarke  MJKaufman  SFAnderson  LJ Bronchiolitis-associated hospitalizations among American Indian and Alaska Native children. Pediatr Infect Dis J. 2000;1911- 17Article
8.
Committee on Infectious Diseases, Committee on Fetus and Newborn, American Academy of Pediatrics, Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSVIGIV. Pediatrics. 1998;1021211- 6Article
9.
Dowell  SFAnderson  LJGary Jr  HE  et al.  Respiratory syncytial virus is an important cause of community-acquired lower respiratory infection among hospitalized adults. J Infect Dis. 1996;174456- 62Article
10.
Whimbey  ECouch  RBEnglund  JA  et al.  Respiratory syncytial virus pneumonia in hospitalized adult patients with leukemia. Clin Infect Dis. 1995;21376- 9Article
×